IL33抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P06446(IL33 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P06446(IL33 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

Interleukin-33 (IL-33), a member of the IL-1 cytokine family, functions as an alarmin released during cellular stress or damage to activate innate and adaptive immunity. It binds to its receptor ST2 (IL-1RL1) and co-receptor IL-1RAcP, triggering signaling pathways like NF-κB and MAPK that drive type 2 immune responses, inflammation, and tissue repair. Dysregulated IL-33/ST2 signaling is implicated in allergic diseases (asthma, atopic dermatitis), fibrotic disorders, and cancer, making it a therapeutic target.

IL-33-targeting antibodies are designed to modulate this pathway. Neutralizing antibodies block IL-33 binding to ST2. suppressing downstream pro-inflammatory effects. Diagnostic antibodies detect IL-33 levels in research or clinical settings. Agonistic antibodies, though less common, may enhance IL-33’s tissue-protective roles. Examples include Astegolimab (anti-ST2) and Etokimab (anti-IL-33), which have shown mixed results in asthma and eczema trials. Challenges include balancing efficacy with potential immunosuppression risks, optimizing tissue-specific delivery, and addressing IL-33’s dual roles in promoting or inhibiting tumors. Current research focuses on antibody engineering (humanization, bispecific designs) and combination therapies. While preclinical data are promising, clinical translation requires further validation of safety and long-term outcomes.